Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug

Anti-Cancer Drug Design

Volumn 13, Issue 8, 1998, Pages 981-993

  Pettit, George R ^a   Rhodes, Monte R ^a   Herald, Delbert L ^a   Chaplin, Dai J ^b   Stratford, Michael R L ^c   Hamel, Ernest ^a   Pettit, Robin K ^a   Chapuis, Jean Charles ^a   Oliva, Deanna ^d  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WESTERN OREGON UNIVERSITY   (United States)

Author keywords

Antimicrobial agents; Antineoplastic agents; Phosphate esters; trans combretastatin A 4 prodrug

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4; PHOSPHORIC ACID; PRODRUG; STILBENE DERIVATIVE;

ARTICLE; DRUG SYNTHESIS; PHOSPHORYLATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MICROBIAL SENSITIVITY TESTS; PRODRUGS; STEREOISOMERISM; STILBENES; TUMOR CELLS, CULTURED;

EID: 0032410472     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. ADAMS, D.J. & KNICK, V.C. (1995). P-glycoprotein resistance to 5′-nor-anhydro-vinblastine (Navelbine®). Investigational New Drugs, 13, 13.
2. ALONSO, E., RAMON, D.J. & YUS, M. (1997). Simple synthesis of 5-substituted resorcinols: a revisited family of interesting bioactive molecules. Journal of Organic Chemistry, 62, 417.
3. AYERS, R.L., MICHEJDA, C.J. & RACK, E.P. (1971). Reaction of iodine with olefins. Kinetics and mechanism of iodine addition to pentene isomers. Journal of the American Chemical Society, 93, 1389.
4. BERINAGA, M. (1997). Designing therapies that target tumor blood vessels. Science, 275, 482.
5. CHEN, G., RAMACHANDRAN, C. & KRISHAN, A. (1993). Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to p-glycoprotein. Cancer Research, 53, 2544.
6. DARK, G.G., HILL, S.A., PRISE, V.E., TOZER, G.M., PETTIT, G.R. & CHAPLIN, D.J. (1997). Combretastatin A-4, an agent that displays potent and selective toxicity towards tumour vasculature. Cancer Research, 57, 1829.
7. GENNE, P., DUCHAMP, O., SOLARY, E., MAGNETTE, J., BELON, J.P. & CHAUFFERT, B. (1995). Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anti-Cancer Drug Design, 10, 103.
8. HASSNER, A., BOERWINKLE, F.P. & LEVY, A.B. (1970). Stereochemistry of halogen azide additions to olefins. The stability of three-membered iodonium vs bromonium ions. Journal of the American Chemical Society, 92, 4879.
9. JANG, M., CAI, L., UDEANI, G.O., SLOWING, K.V., THOMAS, C.F., BEECHER, C.W.W., FONG, H.H.S., FARNSWORTH, N.R., KINGHORN, A.D., MEHTA, R.G., MOON, R.C. & PEZZUTO, J.M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218.
10. KANG, Y. & PERRY, R.R. (1994). Effect of α-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Research, 54, 2952.
11. LIN, C.M., SINGH, S.B., CHU, P.S., DEMPCY, R.O., SCHMIDT, J.M., PETTIT, G.R. & HAMEL, E. (1988). Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin, a structure-activity study. Molecular Pharmacology, 34, 200.
12. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (1997). Performance standards for antimicrobial disk susceptibility tests - sixth edition; approved standard M2-A6. NCCLS, Wayne, PA.
13. PETTIT, G.R. & RHODES, M.R. (1998). Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anti-Cancer Drug Design, 13, 183.
14. PETTIT, G.R., SINGH, S.B., BOYD, M.R., HAMEL, E., PETTIT, R.K., SCHMIDT, J.M. & HOGAN, F. (1995). Antineoplastic Agents 291. Isolation and synthesis of combretastatin A-4, A-5, and A-6. Journal of Medicinal Chemistry, 38, 1666.